drugset / Trial / NCT02663128

A Study of Lanabecestat (LY3314814) in Healthy Participants

NCT02663128

Phase 1 Completed 18 enrolled AstraZeneca Eli Lilly and Company · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to measure how much of a new tablet formulation of lanabecestat gets into the blood stream and how long it takes the body to get rid of it, compared to the current tablet formulation of lanabecestat. The effect of a high fat meal on how quickly the body absorbs the new tablet formulation will also be evaluated. In addition any side effects of the study drug using both the new and current tablet formulations will be evaluated. The study will last about 22 days, with screening required within 30 days prior to the start of the study.

Timeline

Start
2016-01-31
Primary completion
2016-03-31
Completion
2016-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lanabecestat Small molecule 50 mg Oral

Indications

No indication recorded.